Management of liver diseases during the pandemic of coronavirus disease-19

Clin Mol Hepatol. 2020 Jul;26(3):243-250. doi: 10.3350/cmh.2020.0111. Epub 2020 Jun 23.

Authors

Ju-Yeon Cho¹, Soon Sun Kim², Young-Sun Lee³, Do Seon Song⁴, Jeong-Hoon Lee⁵, Ji Hoon Kim³

Affiliations

¹ Department of Internal Medicine, College of Medicine, Chosun University, Gwangju, Korea.
² Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
³ Department of Internal Medicine, Guro Hospital, Korea University College of Medicine, Seoul, Korea.
⁴ Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Seoul, Korea.
⁵ Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.

No abstract available

Keywords: COVID-19; Hepatitis; Hepatocelluar carcinoma; Liver cirrhosis; SARS-CoV-2.

Publication types

Practice Guideline

MeSH terms

Antiviral Agents / therapeutic use
Betacoronavirus / isolation & purification
COVID-19
Carcinoma, Hepatocellular / pathology
Carcinoma, Hepatocellular / therapy
Coronavirus Infections / complications
Coronavirus Infections / drug therapy
Coronavirus Infections / epidemiology
Coronavirus Infections / pathology*
Cross Infection / prevention & control
Drug Interactions
Humans
Immunosuppressive Agents / therapeutic use
Liver Diseases / complications
Liver Diseases / pathology
Liver Diseases / prevention & control*
Liver Neoplasms / pathology
Liver Neoplasms / therapy
Liver Transplantation
Pandemics
Pneumonia, Viral / complications
Pneumonia, Viral / drug therapy
Pneumonia, Viral / epidemiology
Pneumonia, Viral / pathology*
SARS-CoV-2

Substances

Antiviral Agents
Immunosuppressive Agents